EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Contraception
Conditions
Contraception, Female Contraception
Trial Timeline
Aug 1, 2002 → Mar 1, 2003
NCT ID
NCT00254865About EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets). is a phase 1 stage product being developed by Johnson & Johnson for Contraception. The current trial status is completed. This product is registered under clinical trial identifier NCT00254865. Target conditions include Contraception, Female Contraception.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00254865 | Phase 1 | Completed |
Competing Products
20 competing products in Contraception